Does Wegovy reduce belly fat, or is it just overall weight loss?

The misconception worth correcting first: 'spot reduction' and how semaglutide really works

There's a persistent idea that certain medicines or exercises can dissolve fat from a chosen spot. That's not how human physiology works, and it's worth saying plainly: Wegovy does not selectively target your abdomen. No medicine does. Fat is mobilised systemically, your body draws energy from stores across many sites simultaneously, and the pattern varies between individuals.

So why does belly fat seem to shrink noticeably for many people on semaglutide? The likely reason is that visceral fat (the metabolically active tissue packed around organs inside the abdominal cavity) is particularly responsive during periods of significant energy deficit. It turns over faster than subcutaneous fat (the softer layer just beneath the skin), so when semaglutide reduces appetite and lowers calorie intake over weeks and months, the visceral stores tend to fall early and substantially.

Understanding how semaglutide works as a GLP-1 receptor agonist helps here. It slows gastric emptying, signals fullness to the brain, and reduces food-seeking behaviour, the cumulative result being a sustained reduction in energy intake rather than a single metabolic trick aimed at one region. If you want a fuller answer to the question of whether Wegovy helps lose belly fat specifically, the detail is worth reading before drawing conclusions. The belly fat reduction follows from that sustained deficit, not from the medicine working locally on abdominal tissue.

What waist circumference data from the STEP trials actually showed

The STEP 1 trial (68 weeks, semaglutide 2.4mg versus placebo in adults with obesity) reported an average body-weight reduction of around 15% in the treatment group, as published in the New England Journal of Medicine. Alongside total weight, waist circumference decreased substantially, consistent with loss of abdominal fat tissue.

It's worth being precise about what that means. Waist circumference is a proxy measure, it captures both subcutaneous belly fat and, indirectly, changes in the visceral compartment. A meaningful reduction in waist size alongside a 15% average body-weight loss strongly suggests visceral fat was included in that loss. Dedicated imaging studies with GLP-1 medicines in general support this interpretation, showing preferential reductions in visceral adipose tissue relative to subcutaneous fat during active treatment.

If you're weighing up the broader landscape of semaglutide's effect on abdominal fat, those imaging studies add useful colour to what the STEP trial's waist measurements suggest.

One honest caveat: the degree of abdominal fat loss varies between individuals. Starting weight, diet, activity levels, sleep, stress and genetics all influence where and how quickly fat is mobilised. Trials report averages; your experience may sit above or below them.

Why reducing visceral fat matters beyond appearance

This is where the clinical case for Wegovy becomes more than cosmetic. Visceral fat is not inert tissue, it is metabolically active, releasing inflammatory signals and hormones that raise the risk of type 2 diabetes, cardiovascular disease and fatty liver conditions. Reducing it meaningfully can shift those risk markers in the right direction.

The NHS notes that weight management medicines are recommended for their health benefits, not cosmetic ones, a point the MHRA has also made publicly in its guidance on GLP-1 medicines. The NHS medicines page on semaglutide sets out the licensed basis for treatment, which is weight management as a health intervention. If belly fat is your concern, the relevant question for a prescriber is what your overall health picture looks like: waist circumference, comorbidities, BMI and cardiovascular risk factors together.

It is also worth knowing that Wegovy now holds an approval for reducing major cardiovascular event risk in eligible adults, a separate but related indication reflecting the broader metabolic benefits of the treatment beyond the scales.

What to expect realistically, and what comes next if you're considering treatment

Many people feel a mix of hope and scepticism when they first look into this. That's reasonable. Online discussions about weight loss medicines oscillate between breathless enthusiasm and dismissal, and working out what's actually true takes effort. The honest position is that Wegovy produces meaningful, clinically significant fat loss (including abdominal fat) for most people who take it consistently alongside dietary changes, but it is not a guaranteed transformation and it does not override all other factors.

Treatment starts at a low dose and is titrated gradually by your prescriber, usually over several months. Side effects are predominantly gastrointestinal (nausea, constipation, indigestion) and tend to be most noticeable in the early weeks. They often settle as the body adjusts. You can read more about the practical experience of abdominal changes on Wegovy, including what people notice in the first months.

Pricing is worth factoring in early. An overview of what Wegovy costs privately in the UK sets out what a realistic monthly outlay looks like across the dose schedule, which helps with planning. Treatment through a regulated pharmacy includes a clinical consultation, prescription and aftercare, those components matter for safety and should be part of any cost comparison you make.

Wegovy is a prescription-only medicine. The route to it is a clinical assessment, not a purchase. If you'd like that assessment, speak to our prescribers through a free consultation; the review is personal, same-day, and covers your full health picture before any treatment is considered.